10 Sep UW Health and University of Wisconsin selected as one of first clinical sites in the U.S. to test new COVID-19 vaccine
UW Health and the University of Wisconsin School of Medicine and Public Health (SMPH) are among the first sites in the country to study whether an investigational vaccine developed by the pharmaceutical company AstraZeneca can prevent COVID-19, the disease caused by the new coronavirus SARS-CoV-2.
“UW Health and SMPH are proud to be at the forefront of working toward identifying safe, effective solutions to this global pandemic,” says Betsy Nugent, chief clinical research officer at UW Health and the School of Medicine and Public Health. “Our entire team has been working diligently for months to bring this important clinical trial to our state, and now Wisconsinites have an opportunity to be part of solving this crisis.”
The study, which is recruiting participants, is a phase 3 randomized, double-blinded, placebo-controlled clinical trial — the gold standard for measuring the efficacy of investigatory drugs. UW is one of 100 clinical sites around the country to participate in the trial and will enroll approximately 1,600 people over the next eight weeks at University Hospital.
The UW Health arm of the study is led by Dr. William Hartman, assistant professor of anesthesiology at the School of Medicine and Public Health: